Deals
A biosimilar collaboration between Kashiv and Saya aims to expand access to affordable supportive oncology therapies in Mexico and 10 additional Central America and Caribbean markets.
BC Partners has completed its acquisition from Servier of French generics giant Biogaran after the French government allowed the private-equity takeover on condition that BPI France take a minority stake. Meanwhile, former Biogaran CEO Erick Roche has returned to the role after a long stint at Teva.
Just a few days after Alvotech announced global settlements for its Eylea rival, Samsung Bioepis has followed up with its own agreements with the originators.
Sandoz and Alvotech have struck a deal that will see the firms collaborate on multiple biosimilar candidates for the Australian, Canadian and New Zealand markets across therapeutic areas including ophthalmology, immunology and gastroenterology.
Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.
MS Pharma is continuing to capitalize on opportunities for localized manufacturing in the Middle East, with its latest deal with Hetero Biopharma covering five biosimilars.
In line with previously disclosed launch and partnering plans for GLP-1 products, Lupin shook hands with Galenicum, securing commercial rights to injectable semaglutide.
The leading Japanese generics player and local originator will collaborate on technology transfer, contract manufacturing and product succession as part of a cross-sector effort to strengthen supply chains for long-listed and off-patent medicines.
Hyloris and Orion continue to build on their partnership with another value-added medicine collaboration in Europe.
Biocon Biologics has become one of the most prominent global biosimilars firms since its buyout of former partner Viatris’ biosimilars business. With a rumored IPO instead making way for a merger with generics unit Biocon Ltd, the business’s chief Shreehas Tambe sets out the reasons for the move.
Sun terms reports of acquisitive interest in Organon as "speculative," at least for now. Bankers see a potential transaction fit the profile of a 'typical’ Sun deal, which if it occurs also catapults the Indian firm’s foray into biosimilars.
Following a rebrand in 2024 with a mission to expand to global markets, Latvia’s Olpha has started shipping cholesterol management drugs to Mexico after winning a government supply tender.
With needed funds in its pocket, Biocon is prepared to simplify and integrate its growing off-patent medicines portfolio under one roof.
Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.
Transaction adds sterile injectable manufacturing and strengthens the company’s US-based operations.
Latest agreement with Rosemont underscores Hyloris’ value-added medicines strategy and asset-light US partnering.
Taking full ownership of its Hulio adalimumab biosimilar is among a trio of positive updates from India’s Biocon.
Two and a half years after striking a partnership deal with BioFactura for the firm’s ustekinumab biosimilar rival to Stelara, Aurobindo’s CuraTeQ subsidiary has terminated the agreement in line with its “strategic portfolio prioritization.”
Responding to reports that it is considering a deal involving Organon, Samsung Bioepis has told Generics Bulletin that the rumors are false. Meanwhile, the Korean biosimilars specialist is taking over direct control of ranibizumab sales in Europe, as an ustekinumab approval arrives in Japan.
While US sales of the Sandoz-partnered Cimerli (ranibizumab) biosimilar are paused, Formycon has found a new partner in Zydus for its recently approved second Lucentis rival.